Chronic lung allograft dysfunction (CLAD, an umbrella term which encompasses two subtypes—restrictive allograft syndrome (RAS) and bronchiolitis obliterans syndrome (BOS)) remains the major barrier to long-term survival after lung transplantation. CLAD affects approximately 10% of patients each year and has proven a particularly difficult problem to address, with no major improvements in survival for 3 decades. In this chapter, current diagnostic and management paradigms are discussed, as are preventative approaches. Finally, a more optimistic outlook for patients developing CLAD in coming years, based on a better understanding of pathogenesis, is outlined
BACKGROUND: Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograf...
Although chronic lung allograft dysfunction (CLAD) remains the major life-limiting factor following ...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lu...
Chronic lung allograft dysfunction (CLAD) remains a frequent and troublesome complication after lung...
Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term covering di...
Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term mainly to c...
Chronic lung allograft dysfunction (CLAD) is the major limitation of long-term survival after lung t...
International audienceChronic lung allograft dysfunction (CLAD) is the major limitation of long-term...
Chronic lung allograft dysfunction (CLAD) remains a major problem after lung transplantation with no...
Objectives. Lung transplantation remains the only available treatment option for many end-stage lung...
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the main factor limiting long-term survival...
Chronic lung allograft dysfunction is a heterogeneous entity limiting long-term survival after lung ...
Chronic lung allograft dysfunction (CLAD) is the most common cause of mortality in lung transplant r...
Lung transplantation is currently considered as an ultimate live-saving treatment for selected patie...
BACKGROUND: Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograf...
Although chronic lung allograft dysfunction (CLAD) remains the major life-limiting factor following ...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...
Chronic lung allograft dysfunction (CLAD) remains a major hurdle limiting long-term survival post lu...
Chronic lung allograft dysfunction (CLAD) remains a frequent and troublesome complication after lung...
Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term covering di...
Chronic lung allograft dysfunction (CLAD) was recently introduced as an overarching term mainly to c...
Chronic lung allograft dysfunction (CLAD) is the major limitation of long-term survival after lung t...
International audienceChronic lung allograft dysfunction (CLAD) is the major limitation of long-term...
Chronic lung allograft dysfunction (CLAD) remains a major problem after lung transplantation with no...
Objectives. Lung transplantation remains the only available treatment option for many end-stage lung...
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the main factor limiting long-term survival...
Chronic lung allograft dysfunction is a heterogeneous entity limiting long-term survival after lung ...
Chronic lung allograft dysfunction (CLAD) is the most common cause of mortality in lung transplant r...
Lung transplantation is currently considered as an ultimate live-saving treatment for selected patie...
BACKGROUND: Long-term survival after lung transplantation (LTx) is hampered by chronic lung allograf...
Although chronic lung allograft dysfunction (CLAD) remains the major life-limiting factor following ...
Long-term survival after LTx is limited, mainly attributed to the development of chronic lung allogr...